Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Phase 1
Terminated
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic Leukemiat(9;22)Refractory Acute Lymphoblastic LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT03576547
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners
Not Applicable
Active, not recruiting
- Conditions
- Stage I Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8
- Interventions
- Other: CounselingOther: Informational InterventionOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationBehavioral: Telephone-Based Intervention
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT03575832
- Locations
- 🇺🇸
Harris Health System (LBJ), Houston, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer
Not Applicable
Completed
- Conditions
- Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Malignant Neoplasm in the Spine
- Interventions
- Procedure: Computed TomographyOther: Fludeoxyglucose F-18Procedure: Positron Emission Tomography
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT03575949
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
Phase 2
Suspended
- Conditions
- Metastatic Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 123
- Registration Number
- NCT03575611
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Barriers Affecting Physical Activity
Not Applicable
Completed
- Conditions
- Cancer Patients and Physical Activity
- Interventions
- Behavioral: Questionnaires
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT03573375
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia
Phase 2
Terminated
- Conditions
- Acute Lymphoblastic LeukemiaHyperbilirubinemia
- Interventions
- Dietary Supplement: LevocarnitineDrug: Vitamin B Complex
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03564678
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
Phase 2
Active, not recruiting
- Conditions
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and NeckResectable Cutaneous Squamous Cell Carcinoma of the Head and NeckStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT03565783
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
Not Applicable
Active, not recruiting
- Conditions
- Deleterious BRCA1 Gene MutationPremalignant LesionDeleterious BRCA2 Gene MutationDuctal Breast Carcinoma In SituObesityOverweight
- Interventions
- Other: Behavioral, Psychological or Informational InterventionOther: Questionnaire Administration
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT03546972
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Malignant Neoplasms of Urinary TractRenal Cell CarcinomaMetastatic Renal Cell CarcinomaRenal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene FusionsStage IV Renal Cell Cancer AJCC v8Unclassified Renal Cell CarcinomaChromophobe Renal Cell CarcinomaPapillary Renal Cell CarcinomaSarcomatoid Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03541902
- Locations
- 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Regional Care Center-Katy, Houston, Texas, United States
Developing an eLearning Program in Helping Spanish and Portuguese Speaking Cancer Care Providers During Tobacco Use Counselling
Not Applicable
Completed
- Conditions
- Health Care Provider
- Interventions
- Other: Internet-Based InterventionOther: MeetingOther: Survey Administration
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 89
- Registration Number
- NCT03539991
- Locations
- 🇵🇪
Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
🇧🇷Hosptial de Cancer de Barretos, Barretos, Sao Paulo, Brazil
🇨🇴Instituto Nacional De Cancerologia, Bogota, Colombia
© Copyright 2025. All Rights Reserved by MedPath